Multi-lumen catheter

Information

  • Patent Grant
  • 6482171
  • Patent Number
    6,482,171
  • Date Filed
    Monday, January 13, 1997
    27 years ago
  • Date Issued
    Tuesday, November 19, 2002
    21 years ago
Abstract
A multi-lumen catheter having a reinforcing member wrapped around at least one of the lumens in a helical manner. An inflation lumen is positioned outside the reinforcing member for inflating a balloon carried by the catheter. A two-lumen extrusion is bonded to the reinforced lumen to form the multi-lumen catheter. The multi-lumen catheter is particularly useful as an aortic occlusion catheter.
Description




FIELD OF THE INVENTION




The present invention is directed to reinforced hollow tubes and their methods of manufacture and use. A specific application of the present invention is an aortic occlusion catheter for arresting a patient's heart and placing the patient on bypass.




BACKGROUND OF THE INVENTION




The present invention is directed to multi-lumen structures such as cannulae, catheters and the like. A specific application of the present invention is for an aortic occlusion catheter.




Aortic occlusion catheters are used to isolate the patient's coronary arteries from the rest of the arterial system and deliver a cardioplegic fluid to the coronary arteries to arrest heart contractions. Once the patient's heart is stopped and the coronary arteries isolated from the rest of the arterial system, the patient is prepared for surgery on the heart and great vessels. The aortic occlusion catheter has an expandable member, typically a balloon, which is expanded in the ascending aorta to occlude the ascending aorta.




Many conventional catheters are formed by extrusion methods. A problem with conventional extruded catheters is that the catheters can be prone to kinking. Kinking is particularly problematic when the catheter bends around tight-radius curves. Another problem with conventional extruded catheters is that the catheters can be relatively stiff.




SUMMARY OF THE INVENTION




The present invention solves several problems with conventional extruded catheters by providing a reinforcing catheter with increased kink resistance. The reinforced catheter of the present invention is also flexible so that trauma to the patient is minimized and so that the catheter is bent easily around structures such as the aortic arch.




The aortic occlusion catheter is preferably a multi-lumen catheter with the reinforcing member winding around at least one of the lumens in a helical manner.




The catheter also preferably includes an inflation lumen which is not positioned within the helically wound reinforcing coil. The inflation lumen is used to inflate the balloon. An advantage of positioning the inflation lumen outside the reinforcing coil is that the lumen may be easily pierced to provide an inflation outlet for delivering the inflation fluid to the balloon.




These and other aspects of the invention will become apparent with the following description of the preferred embodiments.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

schematically illustrates a cardiac access system employing an endoaortic partitioning catheter.





FIG. 2

is a schematic partly cut-away representation of a patient's heart with the endoaortic partitioning catheter placed within the ascending aorta.





FIG. 3

is a transverse cross-sectional view of the catheter shown in

FIG. 2

taken along the lines


3





3


.




FIG.


4


. is an enlarged view, partially in section, of the retrograde cardioplegia delivery catheter and the pulmonary venting catheter shown in FIG.


1


.





FIG. 5

is a front view of a dual function arterial cannula and introducer sheath for use with the endoaortic partitioning catheter.





FIG. 6

is a cross sectional view of the hemostasis fitting of the dual function arterial cannula and introducer sheath.





FIG. 7

illustrates the cannula of

FIG. 5

with an endoaortic partitioning catheter introduced into the catheter insertion chamber.





FIG. 8

illustrates the cannula of

FIGS. 5 and 6

with the endoaortic partitioning catheter introduced into the patient's femoral artery.





FIG. 9

is a cross-sectional view of a reinforced section for an aortic occlusion catheter.





FIG. 10

is a longitudinal cross-sectional view of the construction of

FIG. 9

around line A—A.





FIG. 11

is a cross-sectional view of reinforced section of

FIGS. 9 and 10

after fusing together the member and coated elongate member.





FIG. 12

is a cross-sectional view of another reinforced section having a member positioned within a coated elongate member.





FIG. 13

is a cross-sectional view of

FIG. 12

after fusing together the member and coated elongate member.





FIG. 14

is a cross-sectional view of yet another reinforced section for the aortic occlusion catheter.





FIG. 15

is a longitudinal cross-sectional view of

FIG. 14

around line B—B.





FIG. 16

shows an aortic occlusion catheter having one of the reinforced sections disclosed herein.





FIG. 17

is a side view of another aortic occlusion catheter;





FIG. 18

is another side view of the aortic occlusion catheter of

FIG. 17

;





FIG. 19

is a longitudinal cross-sectional view showing the method of constructing the catheter of

FIG. 17

;





FIG. 20

is a longitudinal cross-sectional view showing the structure of

FIG. 19

after heating;





FIG. 21

is a cross-sectional view showing the manufacture of the aortic occlusion catheter of

FIG. 17

;





FIG. 22

is a cross-sectional view of the structure of

FIG. 21

after heating.











DETAILED DESCRIPTION OF THE INVENTION




The invention provides a multi-lumen catheter, cannula or the like for introduction into a patient. A specific application of the present invention if for an endovascular catheter for occluding the ascending aorta and arresting the heart. Although a specific application of the present invention is for a multi-lumen aortic catheter, it is understood that the invention may be used in any other catheter, cannula or the like.




The aortic occlusion catheter is useful in performing a variety of cardiovascular, pulmonary, neurosurgical, and other procedures. The procedures include repair or replacement of aortic, mitral, and other heart valves, repair of septal defects, pulmonary thrombectomy, electrophysiological mapping and ablation, coronary artery bypass grafting, angioplasty, atherectomy, treatment of aneurysms, myocardial drilling and revascularization, as well as neurovascular and neurosurgical procedures.




The aortic occlusion catheter is especially useful in conjunction with minimally-invasive cardiac procedures, in that it allows the heart to be arrested and the patient to be placed on cardiopulmonary bypass using only endovascular devices, obviating the need for a thoracotomy or other large incision.




Reference is made to

FIG. 1

which schematically illustrates a cardiac accessing system and the individual components thereof. The system includes an elongated aortic occlusion or endoaortic partitioning catheter


10


which has an expandable member


11


on a distal portion of the catheter which, when inflated as shown, occludes the ascending aorta


12


to separate or partition the left ventricle


13


and upstream portion of the ascending aorta from the rest of the patient's arterial system and securely positions the distal end of the catheter within the ascending aorta. A cardiopulmonary bypass system


18


removes venous blood from the femoral vein


16


through the blood withdrawal catheter


17


as shown, removes CO


2


from the blood, oxygenates the blood, and then returns the oxygenated blood to the patient's femoral artery


15


through the return catheter


19


at sufficient pressure so as to flow throughout the patient's arterial system except for the portion blocked by the expanded occluding member


11


on the aortic occluding catheter


10


. The aortic occluding catheter


10


has an infusion lumen


40


for antegrade delivery of a fluid containing cardioplegic agents directly into the aortic root


12


and subsequently into the coronary arteries


52


,


53


(shown in

FIG. 2

) to paralyze the patient's myocardium. Optionally, a retrograde cardioplegia balloon catheter


20


may be disposed within the patient's venous system with the distal end of the catheter extending into the coronary sinus


21


(shown in

FIG. 4

) to deliver a fluid containing cardioplegic agents to the myocardium in a retrograde manner through the patient's coronary venous system to paralyze the entire myocardium.




The elongated occluding catheter


10


extends through the descending aorta to the left femoral artery


23


and out of the patient through a cut down


24


. The proximal extremity


25


of the catheter


10


which extends out of the patient is provided with a multi-arm adapter


26


with one arm


27


adapted to receive an inflation device


28


. The adapter


26


is also provided with a second arm


30


with main access port


31


through which passes instruments, a valve prosthesis, an angioscope, or to direct blood, irrigation fluid, cardioplegic agents and the like to or from the system. A third arm


32


is provided for monitoring aortic root infusion pressure at the distal end of the catheter and/or for directing blood, irrigation fluid, and the like to or from the system. In the system configuration of

FIG. 1

, the third arm


32


of the multi-arm adapter


26


is connected to a cardiopulmonary bypass line


33


to vent the patient's heart, particularly the left ventricle, and to recover the blood removed and return it to the patient via the cardiopulmonary bypass system. A suitable valve


34


is provided to open and close the bypass line


33


and direct the fluid passing through the bypass line to a discharge line


35


or a line


36


to a blood filter and recovery unit


37


. A return line may be provided to return any filtered blood to the cardiopulmonary bypass system


18


or other blood conservation system.




The details of the aortic occlusion catheter


10


and the disposition of the distal extremity thereof within the aorta are best illustrated in

FIGS. 2 and 3

. As indicated, the catheter


10


includes an elongated catheter shaft


39


which has a first inner lumen


40


for infusion of a cardioplegic agent in fluid communication with the main access port


31


in the second arm of the adapter


26


. Additionally, the infusion lumen


40


may be adapted to facilitate the passage of instruments, a valve prosthesis, an angioscope, irrigation fluid, and the like therethrough and out the distal port


41


in the distal end thereof. A supporting coil


42


may be provided in the distal portion of the first inner lumen


40


to prevent the catheter shaft


39


from kinking when it straightened for initial introduction into the arterial system or when it is advanced through the aortic arch. The shaft


39


is also provided with a second inner lumen


43


which is in fluid communication with the interior of the occluding balloon


11


.




In one embodiment of the system, a retrograde cardioplegia balloon catheter


20


, which is shown in more detail in

FIG. 4

, is introduced into the patient's venous system through the right internal jugular vein


44


and is advanced through the right atrium


45


and into the coronary sinus


21


through the coronary sinus discharge opening


46


in the right atrium. The retrograde catheter


20


is provided with a balloon


47


on a distal portion of the catheter


20


which is adapted to occlude the coronary sinus


21


when inflated. A liquid containing a cardioplegic agent, e.g an aqueous KCl solution, is introduced into the proximal end


48


of the catheter


20


, which extends outside of the patient, under sufficient pressure so that the fluid containing the cardioplegic agent can be forced to pass through the coronary sinus


21


, through the capillary beds (not shown) in the patient's myocardium, through the coronary arteries


50


and


51


and ostia


52


and


53


associated with the respective coronary arteries into the blocked off portion of the ascending aorta


12


as shown. Retrograde delivery catheters are disclosed in U.S. Pat. No. 5,558,644 which is incorporated herein by reference.




A pulmonary venting catheter


54


is also shown in

FIG. 4

disposed within the right internal jugular vein


44


and extending through the right atrium


45


and right ventricle


55


into the pulmonary trunk


56


. Alternatively, the pulmonary venting catheter


54


may be introduced through the left jugular. The catheter


54


passes through tricuspid valve


57


and pulmonary valve


58


. An inflatable occluding balloon


60


may be provided as shown on a distal portion of the pulmonary venting catheter


54


which is inflated to occlude the pulmonary trunk


56


as shown. The pulmonary venting catheter


54


has a first inner lumen


61


which extends from the distal end of the catheter to the proximal end of the catheter which vents fluid from the pulmonary trunk


56


to outside the patient's body either for discharge or for passage to the blood recovery unit and thereby decompresses the left atrium


14


through the pulmonary capillary beds (not shown). The catheter


54


has a second inner lumen


62


which is adapted to direct inflation fluid to the interior of the inflatable balloon


60


.




To set up the cardiac access system, the patient is initially placed under light general anesthesia. The withdrawal catheter


17


and the return catheter


19


of the cardiopulmonary bypass system


18


are percutaneously introduced into the right femoral vein


16


and the right femoral artery


15


, respectively. An incision


24


is also made in the left groin to expose the left femoral artery


23


and the aortic occluding catheter


10


is inserted into the left femoral artery through an incision therein and advanced upstream until the balloon


11


on the distal end of the occluding catheter


10


is properly positioned in the ascending aorta


12


. Note that bypass could similarly be established in the left groin and the aortic occlusion catheter put into the right femoral artery. The retrograde perfusion catheter


20


is percutaneously inserted by a suitable means such as the Seldinger technique into the right internal jugular vein


44


or the subdlavian vein and advanced into the right atrium


45


and guided through the discharge opening


46


into the coronary sinus.




The pulmonary venting catheter


54


is advanced through the right or left internal jugular vein


44


or the subclavian vein (whichever is available after introduction of retrograde perfusion catheter


20


) into the right atrium


45


, right ventricle


55


, and into the pulmonary trunk


56


. The occluding balloon


60


may be inflated if necessary by inflation with fluid passing through the lumen


62


to block the pulmonary trunk


56


and vent blood therein through the lumen


61


where it is discharged through the proximal end of the catheter which extends outside of the patient. Alternatively, the occluding balloon


60


may be partially inflated with air or CO


2


during introduction for flow-assisted placement. The venting of the pulmonary trunk


56


results in the decompressing of the left atrium


14


and, in turn, the left ventricle. In the alternative, the venting catheter


54


may be provided with means on the exterior thereof, such as expanded coils as described in U.S. Pat. No. 4,889,137 (Kolobow), which hold open the tricuspid and pulmonary valves and perform the same function of decompressing the left atrium. See also the article written by F. Rossi et. al. in the Journal of Thoracic Cardiovascular Surgery, 1900;100:914-921, entitled “Long-Term Cardiopulmonary Bypass By Peripheral Cannulation In A Model Of Total Heart Failure,” which is incorporated herein in its entirety by reference.




The operation of the cardiopulmonary bypass unit


18


is initiated to withdraw blood from the femoral vein


16


through catheter


17


, remove CO


2


from and add oxygen to the withdrawn blood and then pump the oxygenated blood through the return catheter


19


to the right femoral artery


15


. The balloon


11


may then be inflated to occlude the ascending aorta


12


, causing the blood pumped out of the left ventricle (until the heart stops beating due to the cardioplegic fluid as discussed hereinafter) to flow through the discharge port


41


into the first inner lumen


40


of the occluding catheter. The blood flows through the inner lumen


40


and out the third arm


32


of the adapter


26


into the bypass line


33


and then into the blood filter and blood recovery unit


37


through the valve


34


and line


36


. For blood and irrigation fluids containing debris and the like, the position of the valve


34


may be changed to direct the fluid through the discharge line


35


.




In a first embodiment of the method, a liquid containing a cardioplegic agent such as KCl is directed through the infusion lumen


40


of the catheter


10


into the aortic root


12


and subsequently into the coronary arteries


52


,


53


to paralyze the patient's myocardium. Alternatively, if a retroperfusion catheter


20


is provided for delivery of the cardioplegic agent, the balloon


47


on the distal extremity of the catheter


20


is inflated to occlude the coronary sinus


21


to prevent fluid loss through the discharge opening


46


into the right atrium


45


. A liquid containing a cardioplegic agent such as KCl is directed through the catheter


20


into the coronary sinus


21


and the pressure of the cardioplegic fluid within the coronary sinus


21


is maintained sufficiently high, (e.g. 40 mm Hg) so that the cardioplegic fluid will pass through the coronary veins, crossing the capillary beds to the coronary arteries


50


and


51


and out the ostia


52


and


53


. The cardioplegic fluid pressure within the coronary sinus


21


should be maintained below 75 mm Hg to avoid pressure damage to the coronary sinus


21


. Once the cardioplegic fluid passes through the capillary beds in the myocardium, the heart very quickly stops beating. At that point the myocardium is paralyzed and has very little demand for oxygen and can be maintained in this state for long periods of time with minimal damage.




With the cardiopulmonary bypass system in operation, the heart completely paralyzed and not pumping, the left atrium and ventricle decompressed and the ascending aorta blocked by the inflated balloon


11


on the occluding catheter


10


, the heart is appropriately prepared for a cardiac procedure.




Inflation of the inflatable member


11


on the distal end of the delivery catheter


10


fixes the distal end of the occluding catheter


10


within the ascending aorta


12


and isolates the left ventricle


13


and the upstream portion of the ascending aorta from the rest of the arterial system downstream from the inflatable member. The passage of any debris or emboli, solid or gaseous, generated during a cardiovascular procedure to regions downstream from the site would be precluded by the inflated balloon


11


. Fluid containing debris or emboli can be removed from the region between the aortic valve and the occluding balloon


11


through the inner lumen


40


of catheter


10


. A clear, compatible fluid, e.g. an aqueous based fluid such as saline delivered through the inner lumen


40


or the cardioplegic fluid discharging from the coronary ostia


52


and


53


, may be maintained in the region wherein the cardiovascular procedure is to be performed to facilitate use of an angioscope or other imaging means that allows for direct observation of the cardiac procedure. Preferably, the fluid pressure in the left ventricle


13


is maintained sufficiently higher than that in the left atrium to prevent blood from the left atrium from seeping into the left ventricle and interfering with the observation of the procedure. The cardiac access system described above is presented to illustrate use of the endoaortic occlusion catheter


10


, however, any other catheters may be used in connection with the endoaortic occlusion catheter


10


and other aortic occlusion catheters described herein.




In a further aspect of the invention, illustrated in

FIGS. 5-8

, the endoaortic partitioning catheter


195


is coupled to an arterial bypass cannula


150


that is specially adapted to serve as a dual purpose arterial bypass cannula and introducer sheath so as to allow the catheter


195


and the cannula


150


to be introduced through the same arterial puncture. The arterial bypass cannula


150


is configured for connection to a cardiopulmonary bypass system for delivering oxygenated blood to the patient's arterial system. The arterial bypass cannula


150


, shown in

FIG. 5

, has a cannula body


151


which is preferably made of a transparent, flexible, biocompatible polyurethane elastomer or similar material. In one preferred embodiment, the cannula body


151


has a 45


i


beveled distal end


153


, a proximal end


152


, a blood flow lumen


157


extending between the proximal end


152


and the distal end


153


, and an outflow port


191


at the distal end


153


. Alternatively, the cannula body


151


can have a straight cut distal end with chamfered or rounded edge. Optionally, a plurality of additional outflow ports may be provided along the length of cannula body


151


, particularly near distal end


153


. The cannula body


151


is tapered from the proximal end


152


to the distal end


153


and, in one preferred embodiment, the tapered cannula body


151


is reinforced with a coil of flat stainless steel wire


154


embedded in the wall of the cannula body


151


. Adjacent to the proximal end


152


of the cannula body


151


, proximal to the reinforcing coil


151


, is a clamp site


151


which is a flexible section of the tubular cannula body


151


that can be clamped with an external clamp, such as a Vorse type tube occluding clamp, forming a hemostatic seal to temporarily stop blood flow through the lumen


157


of the cannula


150


. In a preferred embodiment, the cannula body


151


has a length between about 10 cm and 60 cm, and preferably between about 12 cm and 30 cm. In one particular embodiment, the cannula body


151


has a distal external diameter of approximately 7 mm or 21 French (Charriere scale) and a distal internal diameter of approximately 6.0 mm or 18 French. In a second particular embodiment, the cannula body


151


has a distal external diameter of approximately 7.7 mm or 23 French (Charriere scale) and a distal internal diameter of approximately 6.7 mm or 20 French. Preferably, the proximal end


152


of the cannula body


151


of either embodiment has an internal diameter of approximately ⅜ inch or 9.5 mm. The choice of which embodiment of the arterial bypass cannula


150


to use for a given patient will depend on the size of the patient and the diameter of the artery chosen for the arterial cannulation site. Generally, patients with a larger body mass will require a higher infusion rate of oxygenated blood while on cardiopulmonary bypass, therefore the larger arterial bypass cannula


150


should be chosen if the size of the artery allows.




An adapter assembly


165


is connected to the proximal end


152


of the cannula body


151


. In one preferred embodiment, the adapter assembly


165


and the cannula body


151


are supplied preassembled as a single, sterile, ready-to-use unit. Alternatively, the adapter assembly


165


can be packaged and sold as a separate unit to be connected to the cannula body


151


at the point of use. The adapter assembly


165


has a Y-fitting


158


which is connected to the proximal end


152


of the cannula body


151


. The Y-fitting


158


has a first branch ending in a barbed connector


159


which is configured for fluid connection to tubing


192


from a cardiopulmonary bypass system, as shown in FIG.


8


. To prepare the arterial bypass cannula


150


for insertion into a peripheral artery, such as a patient's femoral artery or brachial artery, by an arterial cutdown or by a percutaneous Seldinger technique, a connector plug


171


, which is molded of a soft, elastomeric material, is placed over the barbed connector


159


. A tapered dilator


167


is passed through a wiper-type hemostasis seal


172


in the connector plug


171


. The wiper-type hemostasis seal


172


is a hole through the elastomeric connector plug


171


that has a slight interference fit with the external adiameter of the dilator


167


. A series of ridges can be molded within the hemostasis seal


172


to reduce the sliding friction on the dilator


167


while maintaining a hemostatic seal. The dilator


167


has a tapered distal tip


169


, a proximal hub


170


with a luer lock connector, and a guidewire lumen


179


, sized for an 0.038 inch diameter guidewire, that runs from the distal tip


169


to the proximal hub


170


. The diameter of the dilator


167


is such that the dilator


167


substantially fills the cannula lumen


157


at the distal end


153


of the cannula body


151


. The length of the dilator


167


is such that the distal tip


169


of the dilator


167


extends approximately 2 to 5 cm, and more preferably 4 to 5 cm, beyond the beveled end


153


of the cannula body


151


when the dilator hub


170


is against the connector plug


170


. The dilator


167


may assume a bend


173


in it at the point where the dilator


167


passes through the Y-fitting


158


when the dilator


167


is fully inserted. One or more depth markers


174


,


175


can be printed on the dilator


167


with a nontoxic, biocompatible ink. One depth marker


174


may be placed so that, when the marker


174


is just proximal to the hemostasis seal


172


on the elastomeric connector plug


171


, the tapered distal tip


169


of the dilator


167


is just emerging from the beveled end


153


of the cannula body


151


. In one particular embodiment, the tapered dilator


167


is made of extruded polyurethane with a radiopaque filler so that the position of the dilator can be verified fluoroscopically.




A second branch of the Y-fitting


158


is connected to an extension tube


162


which terminates in a hemostasis valve


176


configured to receive the endoaortic partitioning catheter


195


therethrough. The extension tube


162


has a flexible middle section which serves as a proximal clamp site


164


that can be clamped with an external clamp, such as a Vorse type tube occluding clamp, forming a hemostatic seal to temporarily stop blood flow through the lumen


163


of the extension tube


162


. The lumen


163


of the extension tube


162


between the proximal clamp site


164


and the hemostasis valve


176


serves as a catheter insertion chamber


166


, the function of which will be more fully explained in connection with FIG.


7


.




In a preferred embodiment of the arterial bypass cannula


150


, the hemostasis valve


176


is a type of compression fitting known in the industry as a Tuohy-Borst adapter. The Tuohy-Borst adapter


176


is shown in greater detail in FIG.


6


. The Tuohy-Borst adapter


176


has a compressible tubular or ring-shaped elastomeric seal


183


that fits within a counterbore


179


in the fitting body


177


. The elastomeric seal


183


is preferably made from a soft, resilient, self-lubricating elastomeric material, such as silicone rubber having a hardness of approximately 20-50 and preferably 40-50 Shore A durometer. The elastomeric seal


183


has a central passage


184


with a beveled entry


185


on the proximal end of the passage


184


. The elastomeric seal


183


has a beveled distal surface


186


angled at about


45




i


which fits against a tapered seat


180


in the bottom of the counterbore


179


that is angled at about


60




i


. A threaded compression cap


187


screws onto the fitting body


177


. The threaded cap


187


has a tubular extension


187


which fits within the counterbore


179


in the fitting body


177


. An externally threaded section


188


on the proximal end of the tubular extension


187


engages an internally threaded section


181


within the proximal end of the counterbore


179


. When the threaded cap


187


is screwed down onto the fitting body


177


, the tubular extension


189


bears on the elastomeric seal


183


forcing it against the tapered seat


180


of the counterbore


179


. The resultant force on the elastomeric seal


183


squeezes the elastomeric seal


183


inward to close off the passage central


184


to make a hemostatic seal. When the threaded cap


187


is unscrewed again from the fitting body


177


, the central passage


184


of the elastomeric seal


183


opens up again. The deliberate


15


; mismatch between the angle of the beveled distal surface


186


of the elastomeric seal


183


and the tapered seat


180


of the counterbore


179


prevents the elastomeric seal


183


from binding and causes the central passage


184


to open up reliably when the threaded cap


187


is unscrewed from the fitting body


187


. An internal ridge


190


within the threaded cap


187


engages in a snap fit with an external ridge


182


on the proximal end of the fitting body


177


to keep the threaded cap


187


from being inadvertently separated from the fitting body


177


if the threaded cap


187


is unscrewed to the point where the threads


188


,


181


are no longer engaged.




In one particular embodiment, the central passage


184


of the elastomeric seal


183


has an internal diameter of about 5 mm to allow clearance for inserting a catheter


195


with a shaft diameter of 3-4 mm through the Tuohy-Borst adapter


176


without damaging the occlusion balloon


196


mounted on it. The Tuohy-Borst adapter


176


is adjustable through a range of positions, including a fully open position for inserting the balloon catheter


196


, a partially closed position for creating a sliding hemostatic seal against the shaft


197


of the catheter


195


, and a completely closed position for creating a hemostatic seal with no catheter in the central passage


184


. In an alternative embodiment, the central passage


184


of the elastomeric seal


183


can be sized to have a slight interference fit with the shaft


197


of the catheter


195


when uncompressed. In this embodiment, the Tuohy-Borst adapter


176


has positions which include a fully open position for creating a sliding hemostatic seal against the shaft


197


of the catheter


195


, and a completely closed position for creating a hemostatic seal with no catheter in the central passage


184


. In a second alternative embodiment, a separate ring-like wiper seal (not shown) is added in series with the Tuohy-Borst adapter


176


to create a passive sliding hemostatic seal against the shaft


197


of the catheter


195


without the necessity of tightening the threaded cap


187


. Additionally, the Tuohy-Borst adapter


176


, in either embodiment, may have a tightly closed position for securing the catheter shaft


197


with respect to the patient. In other alternative embodiments, other known hemostasis valves may be substituted for the Tuohy-Borst adapter


176


as just described.




In a particularly preferred embodiment, the internal surface of the lumen


163


of the extension tube


162


and/or the internal surface of the lumen


157


of the cannula body


151


are coated with a highly lubricious biocompatible coating, such as polyvinyl pyrrolidone, to ease the passage of the endoaortic partitioning catheter


195


, and especially the occlusion balloon


196


, through these lumens. Other commercially available lubricious biocompatible coatings can also be used, such as Photo-Link


a


coating available from BSI Surface Modification Services of Eden Prairie, Minn. sodium hyaluronate coating available from Biocoat of Fort Washington, Pa.; proprietary silicone coatings available from TUA of Sarasota, Fla.; and fluid silicone or silicon dispersions. Similarly, a distal portion of the exterior of the cannula body


151


can be coated with one of these lubricious biocompatible coatings to facilitate insertion of the arterial bypass cannula


150


into the artery at the cannulation site. Furthermore, the endoaortic partitioning catheter


195


itself, in any of the embodiments described herein, can be coated with one of these lubricious biocompatible coatings to facilitate its insertion and passage through the arterial bypass cannula


150


and the patient's vasculature. Preferably, the occlusion balloon


196


of the endoaortic partitioning catheter


195


should be free of any lubricious coating so that there is sufficient friction between the expanded occlusion balloon and the interior aortic wall to prevent accidental dislodgement or migration of the occlusion balloon


196


.




In operation, the arterial bypass cannula


150


is prepared for insertion as shown in

FIG. 5

, with the tapered dilator


167


in place in the blood flow lumen


157


of the cannula body


151


and with the Tuohy-Borst fitting


176


completely closed. An arterial cutdown is made into an artery, preferably the patient's femoral artery, at the cannulation site or a guidewire is placed percutaneously using the Seldinger technique and the dilator


167


and the distal end


153


of the cannula body


151


are inserted into the lumen of the artery with the bevel up. A suture


194


can be tied around the artery


193


where the cannula body


151


, as shown in

FIG. 7

, inserts to avoid bleeding from the artery


193


at the cannulation site. The dilator


167


is then withdrawn from the cannula body


151


, allowing blood to flash back and fill the lumen


157


of the cannula body


151


. When the tip


168


of the dilator


167


is proximal to the distal clamp site


156


an external clamp is applied to the distal clamp site


156


to stop further blood flow. The dilator


167


is completely withdrawn and the connector plug


171


is removed so that a tube


192


from the cardiopulmonary bypass system can be attached to the barbed connector


159


of the Y-fitting


158


, as shown in FIG.


7


. Air is bled from the arterial bypass cannula


150


by elevating the extension tube


162


and opening the Tuohy-Borst fitting


176


slightly and releasing the external on the distal clamp site


156


to allow the blood to flow out through the Tuohy-Borst fitting


176


. Alternatively, air can be bled out of the arterial bypass cannula


150


, through an optional vent fitting with a luer cap (not shown) that can be provided on the Y-fitting


158


or an infusion line and a threeway stopcock. The optional vent fitting can be also used as a port for monitoring perfusion pressure within the arterial bypass cannula


150


. Once the air is bled out of the system, the external clamp can be removed from the distal clamp site


156


the cardiopulmonary bypass system pump can be turned on to perfuse the patient's arterial system with oxygenated blood at a rate of about 3 to 6 liters/minute, preferably at a pump pressure of less than about 500 mm Hg.




To introduce the endoaortic partitioning catheter


195


into the arterial bypass cannula


150


, an external clamp


191


is placed on the proximal clamp site


164


, as shown in

FIG. 7

, to stop blood from flowing out through the extension tube


162


and the Tuohy-Borst adapter


176


is opened all the way by unscrewing the threaded cap


187


to open up the passage


184


through the elastomeric seal


183


. The distal end of the endoaortic partitioning catheter


195


with the occlusion balloon


196


mounted thereon is inserted through the passage


184


of the Tuohy-Borst adapter


176


into the insertion chamber


166


of the arterial bypass cannula


150


. Optionally, first and second depth markers


198


,


199


may be printed on the shaft


197


of the endoaortic partitioning catheter


195


with a nontoxic, biocompatible ink. The first depth marker


198


on the catheter


195


indicates when the occlusion balloon


196


is entirely distal to the elastomeric seal


183


. When the first depth marker


198


is positioned just proximal to the threaded cap


187


, the Tuohy-Borst adapter


176


should be tightened to create a sliding, hemostatic seal around the catheter shaft


197


. Now, the clamp


191


can be removed to allow the catheter


195


to be advanced distally through the arterial bypass cannula


150


.




Before the endoaortic partitioning catheter


195


enters the blood flow lumen


157


within the Y-fitting


158


, the perfusion rate from the cardiopulmonary bypass system pump should be temporarily turned down to a rate of about 1 to 2 liters/minute to avoid hemolysis, tubing disruptions or other complications due to the additional flow resistance caused by the occlusion balloon


196


as it passes through the blood flow lumen


157


. The catheter


195


can now be advanced distally until the occlusion balloon


986


is distal to the distal end


153


of the cannula body


151


. A second depth marker


199


on the catheter


195


indicates when the occlusion balloon


196


is entirely distal to the distal end


153


of the cannula body


151


. When the second depth marker


198


reaches the proximal end of the threaded cap


187


, as shown in

FIG. 7

, the perfusion rate from the cardiopulmonary bypass system pump should be returned to a rate of about 3 to 6 liters/minute. The endoaortic partitioning catheter


195


can now be advanced into the ascending aorta for partitioning the heart and inducing cardioplegic arrest according to the methods described above. When the endoaortic partitioning catheter


195


is in position within the ascending aorta the Tuohy-Borst adapter


176


can be tightened around the catheter


195


to act as a friction lock to hold the catheter in place.




After completion of the surgical procedure on the heart, the endoaortic partitioning catheter


195


can be removed from the arterial bypass cannula


150


by reversing the sequence of operations described above. The arterial bypass cannula


150


can remain in place until the patient has been weaned from cardiopulmonary bypass, then the arterial bypass cannula


150


can be removed and the arterial puncture site repaired. The arterial bypass cannula


150


is described to illustrate the relationship between the endoaortic partitioning catheter


195


and arterial bypass cannula


150


. Another preferred arterial bypass cannula is described in co-pending U.S. Pat. No. 5,863,366 entitled “Cannula and Method of Manufacture and Use,” issued Jan. 26, 1999 by inventor David Snow, which is hereby incorporated by reference.




It should be noted that for the venous side of the cardiopulmonary bypass system, a similar dual purpose venous bypass cannula and introducer sheath with the above-described features can be used for accessing the femoral vein and for introducing a venting catheter or other devices into the venous side of the circulatory system. In a venous configuration the dual purpose venous bypass cannula and introducer sheath preferably has an external diameter of about 21 to 32 French units, an internal diameter of about 18 to 30 French units, and a length of about 50 to 75 cm.




Referring to

FIGS. 9 and 10

, a preferred structure for a reinforced section


205


of a catheter, cannula or the like is shown. An elongate member


207


is coated with a coating


209


. The coating


209


is preferably extruded over the elongate member


207


but may be applied in any other manner such as dipping. The elongate member


207


may be made of any suitable material which has the requisite structural characteristics such as stainless steel, nickel titanium or a polymer. A preferred material is stainless steel ribbon having a width of between 0.006 and 0.012 inch and a height of between 0.002 and 0.004 inch. The elongate member


207


may have any cross-sectional shape, such as circular, and a preferred cross-sectional shape is a quadrangle. Any suitable coating


209


may be used and preferred coatings include polymers and specifically polyurethane, rubber, PVC or any thermoplastic elastomer.




The coating


209


is extruded over the elongate member


207


so that the coating


209


has opposing sides


211


,


212


which are configured to engage one another when the coated elongate member


207


is wrapped around a mandrel


213


M. A preferred shape is a quadrangle, however, any other shape may be used including irregular shapes so long as the opposing sides


211


,


212


are configured to engage one another. The coating


209


preferably has a height of 0.006 to 0.014 inch and more preferably 0.008 to 0.012 inch and most preferably 0.008 to 0.010 inch. The coating


209


also has a length of 0.012 to 0.026 inch and more preferably 0.012 to 0.018 inch and most preferably 0.016 to 0.018 inch. The resulting thickness of the reinforced section


205


provides a thin walled tube which resists kinking.




The coated elongate member


207


is then wrapped around the mandrel


213


in a helical manner. The coated elongate member


207


is wound so that a first lumen


215


is formed when the mandrel


213


is removed. The first lumen has a D-shaped cross-sectional shape which has an arcuate portion


217


extending around at least 120 (degrees) and more preferably at least 180 (degrees). The arcuate portion


217


is preferably a segment of a circle. The mandrel


213


is preferably coated with a lubricious coating such as TFE to prevent sticking. Although the first lumen


215


is preferably D-shaped, it may take any other shape including circular or oval. Furthermore, although it is preferred to coat the elongate member


207


with the coating


209


and wind the coated elongate member


207


around the mandrel


213


, the coated elongate member


207


may be formed by any other method such as dipping or coextrusion.




A member


219


is positioned on top of coated elongate member


207


after the coated elongate member


207


has been wound around the mandrel


213


. The member


219


is preferably W-shaped so that second and third lumens


221


,


223


are formed when the member


219


is positioned on top of the coated elongate member


207


. Blockers


225


, which are preferably made of Teflon, are inserted into the second and third lumens


221


,


223


so that they don't collapse when the reinforced section


205


is heated as will be discussed below. Although it is preferred that the member


219


has two open channels, the member


219


may include two closed channels which for the second and third lumens


221


,


223


without departing from the scope of the invention. An advantage of using the open channel design of the member


219


is that the overall size of the reinforced section


205


is minimized. The member


219


is preferably made of a polymer and a preferred polymer is preferably the same as for coating


209


, however, the member


219


preferably has a higher durometer than the coating


209


so that the coating


209


provides increased bendability while the member


219


provides pushability and kink resistance. The member


219


preferably has a thickness of 0.003 to 0.010 inch and more preferably 0.005 to 0.008 inch.




A heat shrink tube (not shown) is then positioned around the coated elongate member


207


and member


219


. The coated elongate member


207


and the member


219


are then heated to melt the coating


209


and member


219


so that they fuse together to form an integrated structure. Referring to

FIG. 11

the reinforced section


205


is then cooled and the shrink tube, blockers


225


and mandrel


213


are removed. The resulting reinforced section


205


preferably has a circular cross-sectional shape, however, any other shape may be used. Although it is preferred to heat the coated elongate member


207


and member


219


together, a solvent may also be used to bond the two members


207


,


219


together. The resulting reinforced section


205


preferably has a cross-sectional area of 0.0135 to 0.0154 inch(squared) and more preferably 0.0135 to 0.0145 inch(squared) which corresponds to an outer diameter of 0.131 to 0.140 inch and more preferably 0.131 to 0.136 inch. The resulting reinforced section


205


minimizes the size of the catheter while providing sufficient structural characteristics to prevent kinking when the catheter extends around the aortic arch. The first lumen


215


has a cross-sectional size of 0.00754 to 0.01053 inch(squared) and more preferably 0.00817 to 0.01053 inch(squared). The third lumen


223


preferably has a cross-sectional size of 0.00095 to 0.0015 inch(squared) and more preferably 0.0010 to 0.0012 inch(squared).




Referring to

FIG. 12

, another reinforced section


205


A is shown. The reinforced section


205


A includes an elongate member


207


A coated with a coating


207


A. The elongate member


207


A and coating


209


A may be any of the elongate members and coatings described above and is preferably the same as the elongate member


207


and coating


209


of the reinforced section


205


. A member


211


A and blockers


215


A are positioned on the member


211


A. The coated elongate member


207


A is then wrapped around the mandrel


213


A, member


211


A, and blockers


215


A in a helical manner. The coated elongate member


207


A preferably has the same cross-sectional shape as the coated elongate member


207


and the coated elongate member


207


A is wrapped so that adjacent portions of the coated elongate member


207


A engage one another in the manner described above. Although it is preferred to coat the elongate member


207


A with the coating


209


A and wind the coated elongate member around the mandrel


213


A, member


211


A and blockers


215


N, the coated elongate member


207


A may be formed by any other method such as dipping or coextrusion.




The member


211


A is preferably T-shaped but may take any other shape which forms first, second and third lumens


219


A,


221


A,


223


A. The blockers prevent the second and third lumens


221


A,


223


A from closing when the coated elongate member


207


A and member


211


A are fused together. A shrink tube (not shown) is positioned around the coated elongate member


207


A and the coated elongate member


207


A and member


211


A are heated to produce the integrated structure of

FIG. 813

The reinforced section


205


A preferably has the same dimensions as the reinforced section


205


and the first, second and third lumens


219


N,


221


N,


223


preferably have the same dimensions as the aortic occlusion catheters described above.




Referring to

FIG. 14

, yet another reinforced section


205


B is shown. The reinforced section


205


B includes an extrusion


302


, which forms a single integrally foremost structure preferably having first, second and third lumens


304


,


306


,


308


An elongate member


310


, which may be any of the elongate members described herein, is wrapped around the extrusion


302


. A preferred elongate member


310


is a stainless steel ribbon having a width of 0.003 inch and a height of 0.012 inch. Referring to

FIG. 15

, the elongate member


310


is preferably wound so that adjacent portions are spaced apart between 0.010 and 0.020 inch. A tube


312


, which is preferably made of polyurethane and preferably has a thickness of between 0.002 and 0.006 inch, is positioned over the elongate member


310


. A shrink tube (not shown) is then positioned over the tube


312


and blockers are positioned in the lumens


304


,


306


,


308


. The tube


312


and extrusion


302


are then heated so that they bond together and form an integral structure with the elongate member


310


. The shrink tube, mandrel and blockers are removed and the resulting structure is essentially the same as the reinforced section


205


of FIG.


13


. Although it is preferred to provide the tube


312


, the elongate member


310


may also be dipped in a polymer solution to encase the elongate member


310


in polymer.




Referring to

FIG. 16

, the reinforced sections


205


,


205


A,


205


B are useful for reinforcing an aortic occlusion catheter


314


. The aortic occlusion catheter


314


may take any of the forms described herein and the entire discussion of aortic occlusion catheters is incorporated here including, for example, all preferred dimensions, shapes and methods of use. The aortic occlusion catheter


314


has an occluding member


315


, which is preferably an inflatable balloon, at the distal end.




The reinforced section


205


is preferably formed so that first, second and third lumens


316


,


318


,


320


wind in a helical manner as shown in FIG.


16


. By winding the reinforced section


250


in a helical manner the reinforced section


205


does not have any particular axis which is susceptible to kinking. It has been found that upon winding the coated elongate members around the mandrel and heating the elongate members, the resulting reinforced section twists when cooled so that the reinforced section naturally has the helical shape. Alternatively, the catheter may be twisted after forming or may be twisted during heating if pliable mandrels and blockers are used. Although it is preferred to wind the reinforced section


205


in a helical manner, the reinforced section


205


may also be formed without twisting. The first lumen


316


is used for infusion of cardioplegic fluid and an outlet


322


is provided distal to the occluding member


315


for infusing cardioplegic fluid to a patient's ascending aorta in the manner described above. The second lumen


318


also has an outlet


324


distal to the occluding member


315


which is preferably used for sensing a pressure in the patient's ascending aorta. The third lumen


320


is fluidly coupled to the occluding member


315


through an outlet


326


for inflating the occluding member


315


. An advantage of using the reinforced section


205


is that the reinforcing coil does not extend around the inflation lumen


320


so that the reinforcing coil does not have to be penetrated when creating the outlet


326


in the inflation lumen


320


. The reinforced section


205


extends around the shaped-end of the aortic occlusion catheter


314


which is particularly susceptible to kinking. The shaped-end of the aortic occlusion catheter


314


is preferably curved to facilitate placement of the occluding member


315


in the ascending aorta. The distal end is also preferably offset from a proximal portion in the manner described below in connection with

FIGS. 17 and 18

.




The occluding member


315


is preferably mounted to the reinforced section


250


. The occluding member


315


preferably extends beyond the distal tip of the shaft when in the expanded shape (not shown) so that the occluding member acts as a bumper which prevents a distal end


328


from contacting the aorta or the aortic valve. The reinforced section


205


may extend throughout the aortic occlusion catheter


314


but preferably only extends around the portion which passes through the aortic arch. As such, the reinforced section


205


preferably extends 10 inches from a distal end


328


and more preferably 15 inches from the distal end


328


.




Referring to

FIG. 17

, another reinforced aortic occlusion catheter


314


A is shown. The aortic occlusion catheter


314


A is used for the same purpose as the aortic occlusion catheter


314


and like reference numerals refer to like structures. The aortic occlusion catheter


314


A has an occluding member


315


, which is preferably an inflatable balloon, at a distal end. The aortic occlusion catheter


314


A also has first, second and third lumens


316


A,


318


A,


320


A which are used for the same purpose as the lumens


316


,


318


,


320


of the aortic occlusion catheter


314


described above. Each lumen has a connector


319


at a proximal end and the lumen


319


has a bellows


321


connection to increase flexibility and eliminate kinking at the proximal end.




Referring to

FIGS. 17 and 18

, the lumens


316


A,


318


A,


320


A do not wind in a helical manner like the lumens


316


,


318


,


320


of the aortic occlusion catheter


314


but, instead, run straight along the catheter


314


. The lumens


318


A,


320


A, which are for balloon inflation and pressure monitoring, are preferably positioned on the radially inner portion of the catheter


314


A in relation to a curved distal portion


317


A. The curved distal portion


317


A facilitates positioning the occluding member


315


in the ascending aorta. Referring to

FIG. 18

, the curved distal portion is also preferably offset somewhat. The resulting curved distal portion generally conforms to the aortic arch to facilitate placement of the occluding member


315


in the ascending aorta.




Referring to

FIG. 22

, a cross-section of the catheter


314


A is shown. The cross-sectional shape of the catheter


314


A is somewhat egg-shaped but may, of course, also be substantially circular or any other suitable shape. An elongate element


310


A which is described below, reinforces the catheter


314


A. The elongate element


310


A preferably extends throughout the length of the catheter


314


A.




Referring to

FIGS. 19-21

, a preferred method of forming the catheter


314


A is shown.

FIG. 19

shows a longitudinal cross-section of a tube


331


A, preferably a urethane tube, mounted on a teflon-coated mandrel


333


A with the reinforcing elongate element


310


A wound around the tube


331


A in a helical manner. The elongate element


310


A is preferably a wire ribbon having a thickness of 0.003 inch and a width of 0.012 inch. The elongate element


310


A is preferably wrapped around the tube


331


A with a spacing of 0.010 inch. Another tube


335


A is positioned over the elongate member


310


A and a shrink tube (not shown) is positioned over the tube


335


A. The entire structure is then heated to fuse the tubes together to form a reinforced tube


337


A which is shown in longitudinal cross-section in FIG.


20


. The resulting reinforced tube


337


A preferably has an inner diameter of about 0.100 inch and a wall thickness of about 0.010 inch.




Referring to

FIG. 21

, a two-lumen member


339


A is positioned against the reinforced tube


337


A and a shrink tube


341


A is positioned around the member


339


A and reinforced tube


337


A. The two-lumen member


339


A has the lumen


320


A, which is used for inflating the balloon, and the


318


A lumen, which is used for pressure monitoring distal to the occluding member


315


. The two-lumen member


339


A is preferably an extrusion having a D-shaped outer surface in cross-section. The member


339


A and tube


337


A are then heated and the shrink tube


341


A is removed to obtain the egg-shaped cross-sectional shape shown in FIG.


22


. The cross-sectional shape is preferably about 0.145 inch tall and 0.125 inch wide. The inflation lumen


320


A is then pierced to provide an inflation path to the occluding member


315


and the occluding member


315


is then mounted to the catheter


314


A.




The methods and devices disclosed herein have been described in conjunction with catheters, however, it is understood that the methods and apparatus may also be used for constructing any other hollow tubes. While the above is a preferred description of the invention, various alternatives, modifications and equivalents may be used without departing from the scope of the invention. For example, the opposing sides of the coated elongate member


207


may have an S-shape, and the reinforced section


205


may have a varying wall thickness. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the claims.



Claims
  • 1. A method of forming a catheter for occluding a patient's ascending aorta and delivering cardioplegic fluid to the patient's heart, comprising the steps of:providing a single integrally formed structure having a first lumen and a second lumen, the first lumen having a cross-sectional size of 0.00754 to 0.01053 inch2; winding a helical reinforcing member around the single integrally formed structure, the helical reinforcing member having a thickness of between 0.006 and 0.012 and a height of between 0.002 and 0.004 inch; positioning an outer wall around the helical reinforcing member, the outer wall having an outer diameter of 0.131 to 0.140 inch; attaching an occluding member to the outer wall, the occluding member being movable from a collapsed condition to an expanded condition, the occluding member being configured to occlude a patient's ascending aorta when in the expanded condition.
  • 2. The method of claim 1, wherein:the second lumen has a cross-sectional size of 0.00095 to 0.0015 inch2.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of Ser. No. 08/664,716 filed Jun. 17, 1996 and now U.S. Pat. No. 5,879,499 which is a continuation-in-part of U.S. patent application Ser. No. 08/612,230 by Snow et al., filed Mar. 7, 1996, now abandoned which is a continuation-in-part of Ser. No. 08/486,216 now U.S. Pat. No. 5,766,151, filed Jun. 7, 1995 which is a continuation-in-part of U.S. patent application Ser. No. 08/282,192, filed Jul. 28, 1994 now U.S. Pat No. 5,584,803, which is a continuation-in-part of application Ser. No. 08/162,742, filed Dec. 3, 1993, now abandoned which is a continuation-in-part of application Ser. No. 08/123,411, filed Sep. 17, 1993, now abandoned which is a continuation-in-part of application Ser. No. 07/991,188, filed Dec. 15, 1992, now abandoned which is a continuation-in-part of application Ser. No. 07/730,559, and now U.S. Pat. No. 5,370,685, filed Jul. 16, 1991. This application is also related to copending U.S. Pat. No. 05/725,496, filed Nov. 30, 1993, which is a divisional application of U.S. Pat. No. 05,433,700 which is a U.S. counterpart of Australian Patent Application No. PL 6170, filed Dec. 3, 1992. This application is also related to copending U.S. patent application Ser. No. 08/281,962, filed Jul. 28, 1994, now abandoned which is a continuation-in-part of application U.S. Pat. No. 05,571,215, filed Dec. 6, 1993, which is a continuation-in-part of application U.S. Pat. No. 5,452,733, filed Feb. 22, 1993. This application is also related to copending U.S. Pat. No. 5/735,290, filed Jul. 28, 1994, which is a continuation-in-part of U.S. Pat. No. 5/452,733, filed Feb. 22, 1993. This application is also related to copending U.S. Pat. No. 5,458,574, filed Mar. 16, 1994. The complete disclosures of all of the aforementioned U.S. patent applications and patents are hereby incorporated herein by reference for all purposes.

US Referenced Citations (293)
Number Name Date Kind
150960 Isbell May 1874 A
231601 Meigs Aug 1880 A
243396 Pfarre Jun 1881 A
280225 Noe Jun 1883 A
299622 Chase Jun 1884 A
303757 Sears et al. Aug 1884 A
1282881 Landis Oct 1918 A
2029236 Klophaus Jan 1936 A
2308484 Auzin et al. Jan 1943 A
2531730 Henderson Nov 1950 A
2854982 Pagano Oct 1958 A
3326648 Provisor Jun 1967 A
3385300 Holter May 1968 A
3409013 Berry Nov 1968 A
3587115 Shiley Jun 1971 A
3635223 Klieman Jan 1972 A
3671979 Moulopoulos Jun 1972 A
3674014 Tillander Jul 1972 A
3692018 Goetz et al. Sep 1972 A
3755823 Hancock Sep 1973 A
3766924 Pidgeon Oct 1973 A
3769960 Robinson Nov 1973 A
3788328 Alley et al. Jan 1974 A
3833003 Taricco Sep 1974 A
3837347 Tower Sep 1974 A
3889686 Duturbure Jun 1975 A
3903895 Alley et al. Sep 1975 A
3915171 Shermeta Oct 1975 A
3963028 Cooley et al. Jun 1976 A
3970090 Loiacono Jul 1976 A
3983879 Todd Oct 1976 A
4000739 Stevens Jan 1977 A
4019515 Kornblum et al. Apr 1977 A
4029104 Kerber Jun 1977 A
4038703 Bokros Aug 1977 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4122858 Schiff Oct 1978 A
4154227 Krause et al. May 1979 A
4173981 Mortensen et al. Nov 1979 A
4204328 Kutner May 1980 A
4222126 Boretos et al. Sep 1980 A
4248224 Jones Feb 1981 A
4285341 Pollack Aug 1981 A
4287892 Schiff Sep 1981 A
4290428 Durand et al. Sep 1981 A
4297749 Davis et al. Nov 1981 A
4301803 Handa et al. Nov 1981 A
4302261 Simkins et al. Nov 1981 A
4304239 Perlin Dec 1981 A
4323071 Simpson et al. Apr 1982 A
4327709 Hanson et al. May 1982 A
4328056 Snooks May 1982 A
4343048 Ross et al. Aug 1982 A
4343672 Kanao Aug 1982 A
4351341 Goldberg et al. Sep 1982 A
4405313 Sisley et al. Sep 1983 A
4411055 Simpson et al. Oct 1983 A
4413989 Schjeldahl et al. Nov 1983 A
4417576 Baran Nov 1983 A
4430081 Timmermans Feb 1984 A
4439186 Kuhl Mar 1984 A
4441495 Hicswa Apr 1984 A
4451251 Osterholm May 1984 A
5314418 Takano et al. May 1984 A
4456000 Schjeldahl et al. Jun 1984 A
4459977 Pizon Jul 1984 A
4284073 Krause et al. Aug 1984 A
4464175 Altman et al. Aug 1984 A
4493697 Krause et al. Jan 1985 A
4496345 Hasson Jan 1985 A
4497325 Wedel Feb 1985 A
4512762 Spears Apr 1985 A
4527549 Gabbay Jul 1985 A
4531935 Berryessa Jul 1985 A
4531936 Gordon Jul 1985 A
4535757 Webster, Jr. Aug 1985 A
4540399 Litzie et al. Sep 1985 A
4552558 Muto Nov 1985 A
4573966 Weikl et al. Mar 1986 A
4574803 Storz Mar 1986 A
4577543 Wilson Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4596552 DeVries Jun 1986 A
4601706 Aillon Jul 1986 A
4601713 Fuqua Jul 1986 A
4610661 Possis et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
3416531 Edwards Dec 1986 A
4631052 Kensey Dec 1986 A
4639252 Kelly et al. Jan 1987 A
4648384 Schmukler Mar 1987 A
4664125 Pinto May 1987 A
4665604 Dubowik May 1987 A
4681117 Brodman et al. Jul 1987 A
4686085 Osterholm Aug 1987 A
4689041 Corday et al. Aug 1987 A
4692148 Kantrowitz et al. Sep 1987 A
4697574 Karcher et al. Oct 1987 A
4705507 Boyles Nov 1987 A
4714460 Calderon Dec 1987 A
4721109 Healey Jan 1988 A
4722347 Abrams et al. Feb 1988 A
4723550 Bales et al. Feb 1988 A
4723936 Buchbinder et al. Feb 1988 A
4733665 Palmaz Mar 1988 A
4764324 Burnham Mar 1988 A
4741328 Gabbay May 1988 A
4751924 Hammerschmidt et al. Jun 1988 A
4753637 Horneffer Jun 1988 A
4767409 Brooks Aug 1988 A
4770652 Mahurkar Sep 1988 A
4771777 Horzewski et al. Sep 1988 A
4777951 Cribier et al. Oct 1988 A
4785795 Singh Nov 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4790825 Bernstein et al. Dec 1988 A
4794928 Kletschka Jan 1989 A
4795439 Guest Jan 1989 A
4796629 Grayzel Jan 1989 A
4798588 Aillon Jan 1989 A
4804358 Karcher et al. Feb 1989 A
4804365 Litzie et al. Feb 1989 A
4808165 Carr Feb 1989 A
4809681 Kantrowitz et al. Mar 1989 A
4811737 Rydell Mar 1989 A
4821722 Miller et al. Apr 1989 A
4830849 Osterholm May 1989 A
4842590 Tanabe et al. Jun 1989 A
4848344 Sos et al. Jul 1989 A
4850969 Jackson Jul 1989 A
4856516 Hillstead Aug 1989 A
4865581 Lundquist et al. Sep 1989 A
4877031 Conway et al. Oct 1989 A
4877035 Bogen et al. Oct 1989 A
4878495 Grayzel Nov 1989 A
4883458 Shiber Nov 1989 A
4886507 Patton et al. Dec 1989 A
4889137 Kolobow Dec 1989 A
4898168 Yule Feb 1990 A
4899787 Ouchi et al. Feb 1990 A
4902272 Milder et al. Feb 1990 A
4902273 Choy et al. Feb 1990 A
4917667 Jackson Apr 1990 A
4923450 Maeda et al. May 1990 A
4927412 Menasche May 1990 A
4934996 Mohl et al. Jun 1990 A
4943275 Stricker Jun 1990 A
4943277 Bolling Jun 1990 A
RE33258 Onik et al. Jul 1990 E
4944729 Buckberg et al. Jul 1990 A
4950245 Brown et al. Aug 1990 A
4960412 Fink Oct 1990 A
4966604 Reiss Oct 1990 A
4969470 Mohl et al. Nov 1990 A
4979939 Shiber Dec 1990 A
4985014 Orejola Jan 1991 A
4986830 Owens et al. Jan 1991 A
4990143 Sheridan Feb 1991 A
4994032 Sugiyama et al. Feb 1991 A
4994033 Shockey et al. Feb 1991 A
5047041 Samuels Mar 1991 A
5007896 Shiber Apr 1991 A
5009636 Wortley et al. Apr 1991 A
5011468 Lundquist et al. Apr 1991 A
5011469 Buckberg et al. Apr 1991 A
5011488 Ginsberg Apr 1991 A
5013296 Buckberg et al. May 1991 A
5015232 Maglinte May 1991 A
5021044 Sharkaway Jun 1991 A
5021045 Bucksberg et al. Jun 1991 A
5024668 Peters et al. Jun 1991 A
5026366 Leckrone Jun 1991 A
5033998 Corday et al. Jun 1991 A
4276874 Wolvek et al. Jul 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5041093 Chu Aug 1991 A
5041098 Loiterman et al. Aug 1991 A
5049132 Shaffer et al. Sep 1991 A
5053008 Bajaj Oct 1991 A
5059167 Lundquist et al. Oct 1991 A
5061257 Martinez et al. Oct 1991 A
5069662 Bodden Dec 1991 A
5080660 Buelna Jan 1992 A
5089015 Ross Feb 1992 A
5112305 Barath et al. Mar 1992 A
5106368 Uldall et al. Apr 1992 A
5109859 Jenkins May 1992 A
5116305 Milder et al. May 1992 A
5125903 McLaughlin et al. Jun 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163905 Michael Nov 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5171218 Fonger et al. Dec 1992 A
5171232 Castillo et al. Dec 1992 A
5176619 Segalowitz Jan 1993 A
5176660 Truckai Jan 1993 A
5181518 McDonagh et al. Jan 1993 A
5186713 Raible Feb 1993 A
5190520 Fenton, Jr., et al. Mar 1993 A
5195942 Weil et al. Mar 1993 A
5197952 Marcadis et al. Mar 1993 A
5216032 Manning Jun 1993 A
5219326 Hattler Jun 1993 A
5221255 Mahurkar et al. Jun 1993 A
5226427 Buckberg et al. Jul 1993 A
5236413 Feiring Aug 1993 A
5246007 Frisbie et al. Sep 1993 A
5250038 Melker et al. Oct 1993 A
5250069 Nobuyoshi et al. Oct 1993 A
5254089 Wang Oct 1993 A
5254097 Schock et al. Oct 1993 A
5270005 Raible Dec 1993 A
5275622 Lazarus et al. Jan 1994 A
5290230 Ainsworth et al. Mar 1994 A
5290231 Marcadis et al. Mar 1994 A
5295958 Shturman Mar 1994 A
5300025 Wantink Apr 1994 A
5304132 Jang May 1994 A
5308320 Safar et al. May 1994 A
5312344 Grinfeld et al. May 1994 A
5322500 Rickerd Jun 1994 A
5322509 Rickerd Jun 1994 A
5324260 O'Neill et al. Jun 1994 A
5330451 Gabbay Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5330433 Fonger et al. Aug 1994 A
5334142 Paradis Aug 1994 A
5334169 Brown et al. Aug 1994 A
5069661 Trudell Dec 1994 A
5370618 Leonhardt Dec 1994 A
5370640 Kolff Dec 1994 A
5374245 Mahurkar Dec 1994 A
5380282 Burns Jan 1995 A
5382239 Orr et al. Jan 1995 A
5383854 Safar et al. Jan 1995 A
5385548 Williams et al. Jan 1995 A
5395330 Marcadis et al. Mar 1995 A
5395331 O'Neill et al. Mar 1995 A
5397306 Nohuyoshi et al. Mar 1995 A
5397351 Pavcnik et al. Mar 1995 A
5411027 Wiklund et al. May 1995 A
5411479 Bodden May 1995 A
5411552 Andersen et al. May 1995 A
5415634 Glynn et al. May 1995 A
5421825 Farcot Jun 1995 A
5423745 Todd et al. Jun 1995 A
5425708 Nasu Jun 1995 A
5428070 Cooke et al. Jun 1995 A
5429597 DeMello et al. Jul 1995 A
5433700 Peters Jul 1995 A
5433446 Shturman Aug 1995 A
5437633 Manning Aug 1995 A
5439443 Miyata et al. Aug 1995 A
5439720 Choudhury Aug 1995 A
5451207 Yock Sep 1995 A
5456665 Postell et al. Oct 1995 A
5458574 MacHold et al. Oct 1995 A
5464394 Miller et al. Nov 1995 A
5472435 Sutton Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5480424 Cox Jan 1996 A
5487730 Marcadis et al. Jan 1996 A
5496294 Hergenrother et al. Mar 1996 A
5499996 Hill Mar 1996 A
5505698 Booth et al. Apr 1996 A
5509897 Twardowski et al. Apr 1996 A
5514236 Avellanet et al. May 1996 A
5525388 Wand et al. Jun 1996 A
5527292 Adams et al. Jun 1996 A
5533957 Aldea Jul 1996 A
5538513 Okajima Jul 1996 A
5549557 Steinke et al. Aug 1996 A
5562606 Huybregts Oct 1996 A
5578010 Ashby Nov 1996 A
5584803 Sweezer et al. Dec 1996 A
5591129 Shoup et al. Jan 1997 A
5591142 Van Ep Jan 1997 A
5595181 Hubbard Jan 1997 A
5597377 Aldea et al. Jan 1997 A
5599329 Gabbay Feb 1997 A
5658264 Samson Aug 1997 A
5695457 St. Goar et al. Dec 1997 A
5697905 d'Ambrosio Dec 1997 A
5702373 Samson Dec 1997 A
5728063 Preissman et al. Mar 1998 A
5755704 Lunn May 1998 A
5863366 Snow Jan 1999 A
5879499 Corvi Mar 1999 A
Foreign Referenced Citations (36)
Number Date Country
2246526 Mar 1973 DE
0 103 546 Mar 1984 EP
0 335 205 Jan 1985 EP
0 161 045 Nov 1985 EP
0 218275 Apr 1987 EP
0 249 338 May 1987 EP
0 238 106 Sep 1987 EP
0277366 Aug 1988 EP
0 277 367 Aug 1988 EP
0 321 614 Jun 1989 EP
0 350 302 Jul 1989 EP
0 357 003 Mar 1990 EP
0 414 350 Jun 1990 EP
473045 Mar 1992 EP
1097881 Mar 1965 GB
1097882 Mar 1965 GB
1284701 Apr 1971 GB
1414344 May 1973 GB
1467976 Mar 1974 GB
1477665 Apr 1974 GB
1513918 Aug 1975 GB
2056023 Mar 1981 GB
1271508 Nov 1986 SU
1371701 Feb 1988 SU
WO 8103613 Dec 1981 WO
WO 8303204 Sep 1983 WO
WO 8910155 Nov 1989 WO
WO 9101689 Feb 1991 WO
WO 9108791 Jun 1991 WO
WO 9110456 Jul 1991 WO
WO 9117720 Nov 1991 WO
WO 9217118 Oct 1992 WO
WO 9307927 Oct 1992 WO
WO 9505860 Feb 1995 WO
WO 9530447 Nov 1995 WO
WO 9633763 Oct 1996 WO
Non-Patent Literature Citations (60)
Entry
Andersen et al., “Transluminal Implantation of Artificial Heart Valves...” European Heart Journal, 1992;13:704-708.
Baxter Healthcare Corporation, “Fogarty Occlusion Catheter: Instructions for Use,”© 1994.
Buckberg, G.D., “Strategies and Logic of Cardioplegic Delivery to Prevent, Avoid, and Reverse Ischemic and Reperfusion Damage,” J Thorac Vasc Surg, 1987; 93:127-129.
Corday et al., “Symposium on the Present Status of Reperfusion of the Acutely Ischemic Myocardium. Part I,” J. Am Coll Cardiol, 1983; 1(4):1031-1036.
Cosgrove, “Management of the Calcified Aorta: An Alternative Method of Occlusion,” Ann Thorac Surg, 1983;36:718-719.
Crooke et al., “Biventricular Distribution of Cold Blood Cardioplegic Solution Administered by Different Retrograde Techniques,” J Cardiac Thorac Surg, 1991;102(4):631-636.
Datascope FDA 510(k) Application, “Percluder-DL Occluding Balloon,” Oct. 12, 1993.
Derwent Abstract No. 87-190867/27 (1987), SU 127508 (Gorki Kirov Medical Ins.).
DLP, Inc., Directions for Use: Cardioplegic Pressure Cannula with Vent Line, Code #14009 9 Gauge (no date).
DLP Medtronic Alternative Access Cannulae Brochure, © 1995.
DLP Worldwide Medical Innovations, Instrument Listings, pp. 5-9.
Douville et al., “Retrograde Versus Antegrade Cardioplegia: Impact on Right Ventricular Function,” Ann Thorac Surg, 1992; 54:56-61.
Drinkwater et al., “The Use of Combined Antegrade-Retrograde Infusion of Blood Cardioplegic Solution in Pediatric Patients Undergoing Heart Operations,” Thorac and Cardiovascular Surg, 1992; 104(5):1349-1355.
Elecath, “Bain Coronary Sinus Flow Catheter for Jugular Entry,” Catalog No. 75-2337, 1994.
Erath and Stoney, “Balloon Catheter Occlusion of the Ascending Aorta,” Ann Thorac Surg, 1983;35:560-561.
Farcot et al., “New Catheter-Pump System for Diastolic Synchronized Coronary Sinus Retroperfusion (D.S.R.),” Med Prog Technol, 1980; 8(1):29-37.
Farcot et al., “Synchronized Retroperfusion of Coronary Veins for Circulatory Support of Jeopardized Ischemic Myocardium,” Am J Cardiol, 1978; 41:1101-1201.
Foster and Threlkel, “Proximal Control of Aorta with a Balloon Catheter,” Surg Gynecology & Obstetrics, 1971, pp. 693-694.
Gundry et al., “A Comparison of Retrograde of Cardioplegia Versus Antegrade Cardioplegia in the Presence of Coronary Artery Obstruction,” Ann Thorac Surg, 1984; 38(2):124-127.
Gundry, “Modification of Myocardial Ischemic in Normal and Hypertrophied Hearts Utilizing Diastolic Retroperfusion of the Coronary Veins,” J Thorac Cardiovasc Surg, 1982;83:659-669.
Haendchen et al., “Prevention of Ischemic Injury and Early Reperfusion Derangements by Hypothermic Retroperfusion,” J Am Coll Cardiol, 1983; 1(4):1067-1080.
Hammond et al., “Retrograde Coronary Sinus Perfusion: A Method of Myocardial Protection in the Dog During Left Coronary Artery Occlusion,” Ann Surg, 1967; 166(1):139-147.
Ishizaka, “Myocardial Protection by Retrograde Cardiac Perfusion with Cold Medified Krebs Solution through Coronary Sinus During Complete Ischemic Arrest for 120 Minutes, ” J Jpn Assn Thorac Surg, 1977;25(12);:1592-1601.
Kalmbach et al., “Cardioplegia Delivery by Combined Aortic Root and Coronary Sinus Perfusion,” Ann Thorac Surg, 1989; 47:316-317.
Kar and Nordlander, “Coronary Veins: An Alternate Route to Ischemic Myocardium,” Heart and Lung, Mar. 1992, vol. 21, No. 2, pp. 148-155.
Leggett et al., “Fiberoptic Cardioscopy Under Cardiopulmonary Bypass: Potential for Cardioscopy Surgery?” Ann Thorac Surg, 1994;58:222-225.
Lust et al., “Improved Protection of Chronically Inflow-limited Myocardium with Retrograde Coronary Sinus Cardioplegia,” Circulation III, 1988;78(5):217-223.
Markov et al., “Reversal of Acute Myocardial Ischemia in Closed Chest Animals by Retrograde Perfusion of the Coronary Sinus with Arterial Blood,” Acta Cardiologica, 1976; XXXI(3):185-199.
Medex, Inc., MX220 Single Tuohy-Borst Adaptor: Instructions of or Use, 1992.
Medi-Tech, Boston Scientific Corporation, “Occlusion Balloon Catheters: Instructions for Use,” Rev. Jun., 1991.
Medtronic Bio-Medicus, Inc., “Bio-Medicus Cannula Instructions for Use Manual, Sterile and Non-Pyrogenic Single-Use Only,” PN 85281 Rev C(10-91).
Medtronic Bio-Medicus, Inc., “Bio-Medicus Cannula Introducer Instructions for Use Manual,” PN 85146-Rev. C(Jun. 1991).
Medtronic Bio-Medicus Femoral Cannulae advertisement, © 1991.
Medtronic Bio-Medicus Pediatric Cannulae advertisement, © 1991.
Medtronic Bio-Medicus Percutaneous Cannula Kits advertisements, © 1991.
Meerbaum et al., “Diastolic Retroperfusion of Acutely Ischemic Myocardium,” Am J Cardiol, 1976; 37:588-598.
Meerbaum et al., “Hypothermic Coronary Venous Phased Retroperfusion: A Closed-Chest Treatment of Acute Regional Myocardial Ischemia,” Circulation, 1982; 65(7): 1435-1445.
Meerbaum et al., “Retrograde Lysis of Coronary Artery Thrombus by Coronary Venouse Strepokinase Administration,” J Am Coll Cardiol, 1983; 1(5):1262-1267.
Menasche et al., “Cardioplegia by Way of the coronary Sinus for Valvular and Coronary Surgery, ” JACC, 1991; 18(2):628-636.
Menasche et al., “Retrograde Cardioplegia through the Coronary Sinus,” Ann Thorac Surg, 1987; 44:214-216.
Menasche et al., “Retrograde Coronary Sinus Cardioplegia for Aortic Valve Operations: A Clinical Report on 500 Patients,” Ann Thorac Surg, 1990; 49:556-564.
Menasche et al., “Retrograde Warm Blood Cardioplegia Preserves Hypertrophied Myocardium: A Clinical Study,” Ann Thorac Surg, 1994; 57:1429-1435.
“Valvular Heart Disease,” Merck Manual of Diagnosis and Therapy, sixteenth ed, 1992, pp. 546-553.
Ogawa, K. “Aortic Arch Reconstruction Without Aortic Cross-Clamping Using Separate Extracorporeal Circulation,” J Jpn Assn Thorac Surg, 1993; pp. 2185-2190.
Okita et al., “Utilization of Triple-Lumen Balloon Catheter for Occlusion of the Ascending Aorta During Distal Aortic Surgery with Hypothermic Retrograde Cerebral Circulation Technique Through Left Thoracotomy,” Journal of Cardiac Surgery, 1996; 10:699-701.
Peters, W. S., “The Promise of Cardioscopic Surgery,” AustralAs J Cardiac Thorac Surg, 1993; 2(3):152-154.
Pilling Surgical Instruments, Vascular Clamps -Cooley Brochure, p. 385 (no date).
Razi, D..M., “The Challenge of Calcific Aortitis,” J Cardiac Surg, 1993; 8:102-107.
Research Medical, Inc., Cardioplegia Products, Product Catalog 1995.
Research Medical, Inc., Fem Flex Femoral Percutaneous Cannulae, advertisement, Ann Thorac Surg, Jan., 1995, p. A38.
Research Medical, Inc. Product Catalog 1995, Cardioplegia Products.
Ropchan et al., “Salvage of Ischemic Myocardium by Nonsynchronized Retroperfusion in the Pig,” The Journal of Thoracic and Cardiovascular Surgery, Sep. 1992, vol. 104, No. 3, pp. 619-625.
Rossi, “Long-term Cardiopulmonary Bypass by Peripheral Cannulation in a Model of Total Heart Failure,” J Thorac Cardiac Vasc Surg, 1990;100:914-921.
Sabiston, D.C., Textbook of Surgery, 10th Ed., 1972, pp. 2021-2023, 2114-2121.
Sakaguchi et al, “Aortic Valve Replacement and Coronary Artery Bypass,” J Jpn Assoc for Thoracic Surg, 1993;41 (6):1063-1068.
Shumway, “Forward Versus Retrograde Coronary Perfusion for Direct Vision Surgery of Acquired Aortic Valvular Disease,” J Thoracic and Cardiovasc Surg, 1959; 75-80.
Takahashi, M., “Retrograde Coronary Sinus Perfusion for Myocardial protection in Aortic A valve Surgery,” J Jpn Assn Thorac Surg, 1982;30(3):306-318.
Uchida et al, “Percutaneous Cardiomyotomy ad Valvulotomy with Angioscopic Guidance,” American Heart Journal, 1991;121 (4, part I):1221-1224.
Uchida et al., “Percutaneous Fiberoptic Angioscopy of the Cardiac Valves,” Am Heart J, 1991;121(6, part I):1791-1798.
Yamaguchi, A., “A Case of Reoperation Using a Balloon Catheter with Blocked Pars Ascendes Aortae,” Kyobu Geka, 1991; 42(11):961-964.
Continuation in Parts (8)
Number Date Country
Parent 08/664716 Jun 1996 US
Child 08/782113 US
Parent 08/612230 Mar 1996 US
Child 08/664716 US
Parent 08/486216 Jun 1995 US
Child 08/612230 US
Parent 08/282192 Jul 1994 US
Child 08/486216 US
Parent 08/162742 Dec 1993 US
Child 08/282192 US
Parent 08/123411 Sep 1993 US
Child 08/162742 US
Parent 07/991188 Dec 1992 US
Child 08/123411 US
Parent 07/730559 Jul 1991 US
Child 07/991188 US